Initial Public Offering

Evommune, Inc. announced the pricing of its IPO of 9,375,000 shares at $16.00 per share, expected to begin trading on the NYSE (EVMN) on November 6, 2025. The offering is anticipated to close on November 7, 2025, and includes an underwriter option for additional shares. Gross proceeds are projected at $150 million. Morgan Stanley, Leerink Partners, Evercore ISI, and Cantor are joint book-runners. Evommune will use the funds to advance its pipeline of therapies targeting chronic inflammatory diseases.

Harvard Ave Acquisition Corporation (HAVAU) closed its $145 million IPO, offering 14,500,000 units at $10.00 each. Units, trading on Nasdaq under HAVAU since October 23, 2025, consist of Class A ordinary shares and rights, expected to list as HAVA and HAVAR, respectively. The Cayman Islands-based SPAC, managed by D. Boral Capital, will pursue a business combination. Investors should note the risks inherent in SPACs, including target selection and regulatory scrutiny.